ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
about
Neutralization sensitivity of HIV-1 subtype B' clinical isolates from former plasma donors in China.Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide StrategyIdentification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor.3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry InhibitorsTargeting HIV-1 gp41-induced fusion and pathogenesis for anti-viral therapyScreening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors.Significant differences in cell-cell fusion and viral entry between strains revealed by scanning mutagenesis of the C-heptad repeat of HIV gp41Influenza A virus entry inhibitors targeting the hemagglutinin.The potent human immunodeficiency virus type 1 (HIV-1) entry inhibitor HR212 blocks formation of the envelope glycoprotein gp41 six-helix bundle.Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41Design of Small Molecules with HIV Fusion Inhibitory Property Based on Gp41 Interaction AssayHIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strainsA safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoVCreating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines.HIV envelope: challenges and opportunities for development of entry inhibitors.Amphipathic properties of HIV-1 gp41 fusion inhibitors.Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocketComputer-Aided Approaches for Targeting HIVgp41.Molecular dynamics modeling the synthetic and biological polymers interactions pre-studied via docking: anchors modified polyanions interference with the HIV-1 fusion mediatorA novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure.A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin.Isolation of Anti-HIV Components fromCanarium albumFruits by High-Speed Counter-Current Chromatography
P2860
Q30537665-35893456-5ACA-4ABB-A754-24F783900454Q30661709-9948B252-03E5-4D9F-B268-8ACCF69FCE0AQ33622229-27A6E0E5-FF58-46EE-A184-D9AABACA6767Q33826278-7F77737E-8F80-4C7D-A8CF-67C41B4A73BCQ34151017-28EF120E-5601-4CEA-A66A-C666738BE2F6Q34761552-BC5172D6-5781-4C02-9034-7C17596F9972Q35600803-02C502D1-2ADE-48CB-AFB8-0DF5F119EA18Q35615810-D8B4D93E-E31D-40FC-8065-361C51561285Q36316050-2EFCA592-51BD-4ECD-85BF-34370319315AQ36390483-983012D2-60CC-4FFA-9409-4E7DE31C7C05Q36586898-2DF8FD58-D6D9-4D8D-9E2E-0BBC0F59FF03Q36634815-AC2784B6-FA63-4DCD-A028-68C84B6537AAQ36643050-5D0E939D-0922-4544-AC57-C8C5C89E319AQ36946831-7FCFDB78-4530-4033-BFE7-0F7520B98F46Q37036508-5D53495E-859C-4454-A6A4-709734005066Q37152873-540A5107-E9C2-4FC3-A8B2-46729911DC77Q37512905-9657B887-250D-47B8-97B5-3BC2363C85CFQ37825824-AD412C41-7BB5-45C3-91E7-D90A6DA1896AQ37850183-5A037643-AE34-4F6E-87E8-8008004EF503Q37951610-60E7A7F5-4250-451E-8463-0D95255648DDQ38076321-7EDD7440-4618-4FBD-95FA-9265F8A52D2EQ38111393-4607CDDA-2C10-4E01-AAF5-6F843AC35275Q38417439-B6DFA2C0-2E5F-4C0A-A842-86DF2E7AF3D1Q39597147-7782C6D3-7655-4882-8D43-DCEFEB7E606FQ54216810-7CC77BC5-6A23-4E6A-A278-F9110721CC96Q58299028-3DB1CEA9-A0EC-4244-BC6B-007DF6D3CA91
P2860
ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
ADS-J1 inhibits human immunode ...... on-active gp41 core formation.
@en
ADS-J1 inhibits human immunode ...... on-active gp41 core formation.
@nl
type
label
ADS-J1 inhibits human immunode ...... on-active gp41 core formation.
@en
ADS-J1 inhibits human immunode ...... on-active gp41 core formation.
@nl
prefLabel
ADS-J1 inhibits human immunode ...... on-active gp41 core formation.
@en
ADS-J1 inhibits human immunode ...... on-active gp41 core formation.
@nl
P2093
P2860
P356
P1476
ADS-J1 inhibits human immunode ...... on-active gp41 core formation.
@en
P2093
Asim K Debnath
Chenglai Xia
Hongtao Wang
Qinchao Mao
Shuguang Wu
Shuwen Liu
Xiaojuan Li
P2860
P304
P356
10.1128/AAC.00670-09
P407
P50
P577
2009-09-28T00:00:00Z